Vernakalant (Brinavess®)

Assessment Status Assessment process complete
Drug Vernakalant
Brand Brinavess®
Indication For haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.
Assessment Process
Rapid review commissioned 26/10/2010
Rapid review completed 04/11/2010
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 08/04/2011
NCPE assessment completed 04/05/2011
NCPE assessment outcome Reimbursement Recommended in Hospital Setting.

Following review, we recommend reimbursement of vernakalant in the hospital setting.

Technical Summary